PRODUCTS

Restylane logo
Macrolane logo
Deflux logo
Durolane logo
Solesta logo

Q-MED AB
SEMINARIEGATAN 21
752 28 UPPSALA, SWEDEN
Phone: +46-(0)18-474 90 00
Fax: +46-(0)18-474 90 01
E-mail: info@q-med.com

Contact information

INNOVATIVE ESTHETICS AND HOSPITAL HEALTHCARE

Q-Med is a medical device Group that primarily develops, manufactures, markets and sells medical implants.

Esthetics

Q-Med develops products that improve the appearance. When someone experiences a heightened sense of well-being, greater self-esteem or a greater quality of life with the aid of our products, that is beauty for us.

Hospital healthcare

Several of Q-Med's products have been the first on the market. Most of the products are based on the company's patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid.

The company today has approximately 650 co-workers in 20 countries, with almost 400 at the company's head office and production facility in Uppsala. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.


Q-Med's half-year report January-June 2010

Q-Med's half-year report January-June will be released on July 22, 2010, at approx. 10.30 a.m. CET.

There will be a telephone conference in connection with the report on Thursday, July 22 at 11.30 a.m. CET.

Invitation to conference call, read more>>

Half-year report>>

Presentation half-year report>>


Maria Carell new CEO for Q-Med AB

Uppsala April 27, 2010

Maria Carell will succeed Bengt Ågerup as CEO of Q-Med AB on September 1, 2010.

Maria comes from Actavis, where she has successfully built up the Swedish business since 2005. Bengt Ågerup will continue as CEO until Maria Carell takes up her appointment.

Read more

THE Q-MED SHARE

QMED 30/07/2010 11:10:07 -0.77% -0.50 sek, Vol: 8,585
Last: 64.75 sek High: 64.75 sek Low: 64.50 sek
The Q-Med share

Press releases

[ 12/07/2010 08:08:00 ] Q-Med AB invites to Q2 conference call

Press releases

Reports


Financial reports

Sales development